Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.

about

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.

Item

http://www.wikidata.org/entity/Q46251266

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Efficacy of adjuvant chemother ...... r: a single center experience.

@en

Efficacy of adjuvant chemother ...... r: a single center experience.

@nl

type

Item

label

Efficacy of adjuvant chemother ...... r: a single center experience.

@en

Efficacy of adjuvant chemother ...... r: a single center experience.

@nl

prefLabel

Efficacy of adjuvant chemother ...... r: a single center experience.

@en

Efficacy of adjuvant chemother ...... r: a single center experience.

@nl

P1476

Efficacy of adjuvant chemother ...... er: a single center experience

@en

P2093

Andreas Schoetzau

http://www.w3.org/2001/XMLSchema#string

Christoph Rochlitz

http://www.w3.org/2001/XMLSchema#string

Fabienne Schwab

http://www.w3.org/2001/XMLSchema#string

Marcus Vetter

http://www.w3.org/2001/XMLSchema#string

Rosanna Zanetti-Dällenbach

http://www.w3.org/2001/XMLSchema#string

Spyridon Fokas

http://www.w3.org/2001/XMLSchema#string

Thomas Schmid

http://www.w3.org/2001/XMLSchema#string

Uwe Güth

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative chemotherapy for women with operable breast cancer

Understanding and treating triple-negative breast cancer

Breast cancer molecular subtypes: from TNBC to QNBC

Repeated observation of breast tumor subtypes in independent gene expression data sets

Triple-negative breast cancer: an unmet medical need

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Triple-Negative Breast Cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

P304

75617-75626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18118

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ewelina Biskup

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29088896

http://www.w3.org/2001/XMLSchema#string

P932

5650451

http://www.w3.org/2001/XMLSchema#string